Investor Presentaiton
Consolidated Statement of Profit or Loss
(RMB 000s)
Revenue
Cost of services
Gross profit
Other income
Other gains and losses, net
Impairment losses
Selling and marketing expenses
Administrative expenses
Research and development expenses
Share of losses of associates
Finance costs
Profit before tax
Income tax expense
Profit for the year
Profit attributable to owners of the Company
Adjusted for:
Share-based compensation expense
Net foreign Exchange loss/(gain)
Year ended June 30,
2022
3,594,209
(2,175,881)
2023
3,710,850
(2,244,568)
1,418,328
1,466,282
128,757
147,146
468,609
571,836
(28,411)
(29,777)
(80,040)
(88,998)
(321,379)
(350,171)
(110,520)
(128,082)
35,556
63,724
(31,035)
(52,815)
1,479,865
1,599,145
(162,239)
(191,055)
1,317,626
1,408,090
1,192,004
1,388,337
16,673
(1,829)
48,476
(17,659)
Amortization of intangible assets arising from acquisitions
17,225
Change in fair value of financial assets at FVTPL
(347,542)
Adjusted net profit attributable to owners of the Company(1)
876,531
5,472
(529,013)
895,613
●Tigermed (1) Non-IFRS measure
28View entire presentation